Market News AIOpen the app

CANF stock news · Can-Fite BioPharma

Stories about Can-Fite BioPharma (CANF) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for CANF

Follow Can-Fite BioPharma (CANF) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for CANF
Free on the App Store and Google Play, or on the web.
  1. Nov 3, 2026, 2:16 AM ET · Trial

    Can-Fite BioPharma said the Eurasian Patent Office is set to give a patent for its drug Piclidenoson.

    Good for CANF

    Can-Fite received notice that a patent for Piclidenoson is ready to be granted for certain rare diseases. This strengthens its position and is favorable.

  2. Sep 2, 2026, 11:59 AM ET · Market

    Can-Fite BioPharma considers conducting an earlier interim review for its pivotal liver cancer trial.

    Neutral

    Can-Fite BioPharma reported extended survival trends in its Phase 3 trial for Namodenoson, prompting management to consider an earlier interim analysis. Additionally, the company secured a $4 million warrant exercise agreement to fund ongoing clinical operations.